Pain Management

Pain relief with suzetrigine was comparable to that seen with placebo, an issue Vertex plans to address with study design as the drug moves to the pivotal phase 3 trials.

If approved, the nonopioid, centrally acting analgesic would be the first in a new class of medications for fibromyalgia in more than 15 years, Tonix said.

The efficacy of acupuncture treatment for chronic pain is still widely debated. A new study evaluated its effect on one of the most treatment resistant forms of low back pain.

Findings from a recent review highlight the impact of common analgesic medications on sleep patterns in people with chronic pain.

The FDA has set a PDUFA date of January 30, 2025 for the investigational oral nonopioid therapy for acute pain, which could be a first-in-class win for Vertex.

Your daily dose of the clinical news you may have missed.

Findings from a systematic review and meta-analysis showed 1 in 3 youth with chronic pain were diagnosed with anxiety and 1 in 8 were diagnosed with depression.

One in 9 primary care encounters involved a mental health condition, according to an analysis of over 350 million primary care visits.

If approved the selective NaV1.8 pain signal inhibitor would reflect the first new class of pain management medication in more than 20 years.

Get details on the relationship between obesity and mental health conditions, chronic pain, and hypertension, here.